

Advanced Colorectal Cancer: Optimizing Treatment and Outcomes with Immunotherapy

Recorded Podcast

Selected References

Andre T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. 2020 ASCO Virtual Scientific Program. *J Clin Oncol*. 2020;38(suppl): Abstract LBA4.

Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. *J Clin Oncol*. 2020;38(15 suppl): 4040.

Franke AF, Skelton WP, Starr JS, et al. Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches. *J Natl Cancer Inst*. 2019;111(11):1131-1141.

Wallin J, Pishvaian MJ, Hernandez G, et al. Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma. *Cancer Res*. 2016;76(14 suppl): Abstract 2651.

Ciardello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. *Cancer Treat Rev*. 2019;76:22-32.

Marmorino F, Boccaccino A, Germani MM, et al. Immune checkpoint inhibitors in pMMR metastatic colorectal cancer: a tough challenge. *Cancers*. 2020;12(8):2317.

Stein A, Binder M, Goekkurt E, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). *J Clin Oncol*. 2018;38(4 suppl): Abstract 96.

Hermel DJ, Sigal D. The emerging role of checkpoint inhibition in microsatellite stable colorectal cancer. *J Pers Med*. 2019;9(1):5.

Bupathi M, Wu C. Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. *J Gastrointest Oncol*. 2016;7(5):713-720.

Samstein RM, Lee CH, Morris LGT, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet.* 2019;51(2):202-206.

Loupakis F, Depetris I, BIASON P, et al. Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. *Oncologist.* 2020;25(6):481-487.

Morse MA, Hochster H, Benson A. Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy. *Oncologist.* 2020;25(1):33-45.

Wieczorska K, Stolarek M, Stec R. The role of the gut microbiome in colorectal cancer: where are we? where are we going? *Clin Colorectal Cancer.* 2020;19(1):5-12.

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med.* 2018;378(2):158-168.

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.* 2018;36(17):1714-1768.